Biallelic variants in KARS1 are associated with neurodevelopmental disorders and hearing loss recapitulated by the knockout zebrafish.
Lin S-J., Vona B., Barbalho PG., Kaiyrzhanov R., Maroofian R., Petree C., Severino M., Stanley V., Varshney P., Bahena P., Alzahrani F., Alhashem A., Pagnamenta AT., Aubertin G., Estrada-Veras JI., Hernández HAD., Mazaheri N., Oza A., Thies J., Renaud DL., Dugad S., McEvoy J., Sultan T., Pais LS., Tabarki B., Villalobos-Ramirez D., Rad A., Genomics England Research Consortium None., Galehdari H., Ashrafzadeh F., Sahebzamani A., Saeidi K., Torti E., Elloumi HZ., Mora S., Palculict TB., Yang H., Wren JD., Ben Fowler None., Joshi M., Behra M., Burgess SM., Nath SK., Hanna MG., Kenna M., Merritt JL., Houlden H., Karimiani EG., Zaki MS., Haaf T., Alkuraya FS., Gleeson JG., Varshney GK.
PurposePathogenic variants in Lysyl-tRNA synthetase 1 (KARS1) have increasingly been recognized as a cause of early-onset complex neurological phenotypes. To advance the timely diagnosis of KARS1-related disorders, we sought to delineate its phenotype and generate a disease model to understand its function in vivo.MethodsThrough international collaboration, we identified 22 affected individuals from 16 unrelated families harboring biallelic likely pathogenic or pathogenic in KARS1 variants. Sequencing approaches ranged from disease-specific panels to genome sequencing. We generated loss-of-function alleles in zebrafish.ResultsWe identify ten new and four known biallelic missense variants in KARS1 presenting with a moderate-to-severe developmental delay, progressive neurological and neurosensory abnormalities, and variable white matter involvement. We describe novel KARS1-associated signs such as autism, hyperactive behavior, pontine hypoplasia, and cerebellar atrophy with prevalent vermian involvement. Loss of kars1 leads to upregulation of p53, tissue-specific apoptosis, and downregulation of neurodevelopmental related genes, recapitulating key tissue-specific disease phenotypes of patients. Inhibition of p53 rescued several defects of kars1-/- knockouts.ConclusionOur work delineates the clinical spectrum associated with KARS1 defects and provides a novel animal model for KARS1-related human diseases revealing p53 signaling components as potential therapeutic targets.